Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. Among authors: fusco fm. J Antimicrob Chemother. 2024 Jun 3;79(6):1279-1288. doi: 10.1093/jac/dkae081. J Antimicrob Chemother. 2024. PMID: 38581349
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona).
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A; mpox-Icona study group. Mazzotta V, et al. Among authors: fusco fm. EBioMedicine. 2024 Sep;107:105289. doi: 10.1016/j.ebiom.2024.105289. Epub 2024 Aug 22. EBioMedicine. 2024. PMID: 39178746 Free PMC article.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Oropouche virus: A re-emerging arbovirus of clinical significance.
Desai AN, Otter A, Koopmans M, Granata G, Grobusch MP, Tunali V, Astorri R, Jokelainen P, Greub G, Ergönül Ö, Valdoleiros SR, Rovers CP, Di Caro A, Pisapia R, Fusco FM, Pereira do Vale A, Krogfelt KA, Petersen E, Atkinson B. Desai AN, et al. Among authors: fusco fm. IJID Reg. 2024 Sep 25;13:100456. doi: 10.1016/j.ijregi.2024.100456. eCollection 2024 Dec. IJID Reg. 2024. PMID: 39507390 Free PMC article. No abstract available.
Oropouche virus: A re-emerging arbovirus of clinical significance.
Desai AN, Otter A, Koopmans M, Granata G, Grobusch MP, Tunali V, Astorri R, Jokelainen P, Greub G, Ergönül Ö, Valdoleiros SR, Rovers CP, Caro AD, Pisapia R, Fusco FM, Vale APD, Krogfelt KA, Petersen E, Atkinson B. Desai AN, et al. Among authors: fusco fm. Int J Infect Dis. 2024 Dec;149:107251. doi: 10.1016/j.ijid.2024.107251. Epub 2024 Sep 25. Int J Infect Dis. 2024. PMID: 39453835 Free article. No abstract available.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512
Recommendations for Updating Fever and Inflammation of Unknown Origin From a Modified Delphi Consensus Panel.
Wright WF, Stelmash L, Betrains A, Mulders-Manders CM, Rovers CP, Vanderschueren S, Auwaerter PG; International Fever and Inflammation of Unknown Origin Research Working Group. Wright WF, et al. Open Forum Infect Dis. 2024 Jun 10;11(7):ofae298. doi: 10.1093/ofid/ofae298. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38966848 Free PMC article.
The world health organization pandemic agreement draft: considerations by the European Society of Clinical Microbiology and Infectious Diseases Emerging Infections Task Force.
Granata G, Astorri R, Broens EM, Callaby H, Cunha F, Di Caro A, Fusco FM, Greub G, Grobusch MP, Koopmans M, Pereira do Vale A, Pisapia R, Rovers CP, Tostmann A, Tunali V, de Valdoleiros SR, Petersen E. Granata G, et al. Among authors: fusco fm. Clin Microbiol Infect. 2024 Sep;30(9):1095-1099. doi: 10.1016/j.cmi.2024.05.016. Epub 2024 May 29. Clin Microbiol Infect. 2024. PMID: 38821176 No abstract available.
Implications of the 2023-2024 MPXV clade I outbreak in the Democratic Republic of Congo to global public health.
Desai AN, Koopmans M, Otter A, Grobusch MP, Jokelainen P, Atkinson B, Cunha F, Valdoleiros SR, Preda VG, Fusco FM, Rovers CP, Greub G, Di Caro A, Simonsen L, Ntoumi F, Petersen E. Desai AN, et al. Among authors: fusco fm. Clin Microbiol Infect. 2024 Sep;30(9):1092-1094. doi: 10.1016/j.cmi.2024.04.016. Epub 2024 Apr 30. Clin Microbiol Infect. 2024. PMID: 38697394 No abstract available.
99 results